Business
Lexington Announces First Multicenter Clinical Study Site
Lexington Announces First Multicenter Clinical Study Site.
About this update from Lexington Biosciences Inc
[{"type":"text","content":"\nVANCOUVER, British Columbia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the Medical College of Wisconsin as the first site in its multicenter clinical study for the HeartSentry portable cardiovascular health monitor.\n “Our initial trials provided us an extensive data set regarding functional efficacy and safety.” states Company CEO, Eric Willis. “Now we move into the next phase of our clinical study with a much larger demographic alongside diagnosis-specific data points to meet the requirements for FDA submission. The team in Wisconsin have been very helpful and we selected them due to their expertise in the field of endothelial function and cardiovascular medicine along with their proven ability to run clinical trials quickly, efficiently, and with a commitment to data integrity. We plan on announcing our other clinical trial centers shortly and are very pleased with the quality of the broader clinical research team.”   As a research center, the Medical College of Wisconsin is the second largest research institution in the state with $234M invested in research, teaching, training and related purposes in FY 2017, which ultimately leads to improved patient care and health outcomes. Its faculty conducted more than 2,800 research studies, including clinical trials last fiscal year, and overall it is the largest research center in the Milwaukee metropolitan area. Lexington Biosciences is conducting the clinical trial process under the leadership of Dr. Geoff Tison, M.D. M.P.H, and is working closely with several potential partners for the implementation of clinical trial contracts. Dr. Tison and Lexington’s Chief Technical Advisor, Dr. Jonathan Maltz, have reviewed the initial data in order to update patient examination protocols and will collaborate with each new facility to begin enrollment of a suitably large patient sample from their respective clinical databases.  HeartSentry was designed as a diagnostic device offering a new approach to non-invasive measurement and monitoring of cardiovascular health by assessing the function of a patient’s vascular endothelium, the vital innermost lining of the cardiovascula...